Stories about Serum (blood)

Subscribe to Serum (blood)

09.11.2020 – 14:07

Merck KGaA
Merck Announces Out-Licensing Agreement for Investigational Atacicept with Vera Therapeutics

Darmstadt, Germany (ots/PRNewswire) - Not intended for UK and US based media - Merck out-licenses Phase IIb-ready atacicept to Vera Therapeutics - Phase IIa trial conducted by Merck shows promising results in IgA nephropathy (IgAN), also known as "Berger's disease" - Out-licencing deal includes 10% equity in Vera Therapeutics and up to EUR 605 million in development ...

more
18.10.2018 – 07:01

UCB Pharma
UCB Accelerates Anti-FcRn Rozanolixizumab in Myasthenia Gravis Into Confirmatory Development Phase

Brussels (ots/PRNewswire) - - Positive outcomes in proof-of-concept study with subcutaneous rozanolixizumab in patients with myasthenia gravis (MG): clinically meaningful improvement in multiple disease-related endpoints - Strong 68% mean reduction of Serum IgG and IgG Autoantibodies observed - Safety profile ...

more
28.08.2018 – 13:36

Grünenthal Group
Duzallo®, a fixed-dose combination therapy for gout, approved in Europe

Aachen (ots) - Today, Grünenthal announced that the European Commission has followed the positive opinion of the Committee for Medicinal Products for Human Use (CHMP) and granted Duzallo® marketing authorization for the EU/EEA. Duzallo® is a fixed-dose combination (FDC) therapy that combines allopurinol and lesinurad. It is indicated for the treatment of ...

more
29.06.2018 – 01:02

Astellas Pharma Europe Limited
Results From Pivotal Phase 3 PROSPER Trial of XTANDI[TM] (enzalutamide) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Published in New England Journal of Medicine

Tokyo (ots/PRNewswire) - Results show enzalutamide plus androgen deprivation therapy significantly reduced the risk of developing metastases or death by 71 percent compared to placebo plus androgen deprivation therapy[i] FOR EMEA MEDICAL MEDIA ONLY - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji ...

more

1